Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeuticsopen access
- Authors
- Antao, Ainsley Mike; Tyagi, Apoorvi; Kim, Kye-Seong; Ramakrishna, Suresh
- Issue Date
- Jun-2020
- Publisher
- MDPI
- Keywords
- cancer therapy; deubiquitinase; DUB inhibitors; USPs phylogenetic tree; signaling pathways
- Citation
- CANCERS, v.12, no.6, pp 1 - 36
- Pages
- 36
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCERS
- Volume
- 12
- Number
- 6
- Start Page
- 1
- End Page
- 36
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/145612
- DOI
- 10.3390/cancers12061579
- ISSN
- 2072-6694
- Abstract
- Since the discovery of the ubiquitin proteasome system (UPS), the roles of ubiquitinating and deubiquitinating enzymes (DUBs) have been widely elucidated. The ubiquitination of proteins regulates many aspects of cellular functions such as protein degradation and localization, and also modifies protein-protein interactions. DUBs cleave the attached ubiquitin moieties from substrates and thereby reverse the process of ubiquitination. The dysregulation of these two paramount pathways has been implicated in numerous diseases, including cancer. Attempts are being made to identify inhibitors of ubiquitin E3 ligases and DUBs that potentially have clinical implications in cancer, making them an important target in the pharmaceutical industry. Therefore, studies in medicine are currently focused on the pharmacological disruption of DUB activity as a rationale to specifically target cancer-causing protein aberrations. Here, we briefly discuss the pathophysiological and physiological roles of DUBs in key cancer-related pathways. We also discuss the clinical applications of promising DUB inhibitors that may contribute to the development of DUBs as key therapeutic targets in the future.
- Files in This Item
-
- Appears in
Collections - 서울 의생명공학전문대학원 > 서울 의생명과학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.